Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience (MSCLF)
OTHER OTC:MSCLF
Holding MSCLF?
Track your performance easily
MSCLF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.27 - $0.94
Previous Close$0.61
Volume272.50K
Average Volume (3M)72.98K
Market Cap
$66.53M
Enterprise Value$50.16M
Total Cash (Recent Filing)C$23.42M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 27, 2025EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding113,600,814
10 Day Avg. Volume189,898
30 Day Avg. Volume72,982
Standard Deviation0.28
R-Squared0.05
Alpha-0.00222
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)3.39
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.77Price Target Upside26.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Satellos Bioscience News
PremiumCompany Announcements
Satellos Bioscience Secures $40 Million Funding Boost
PremiumCompany Announcements
Satellos Bioscience Announces Public Offering of Shares
PremiumCompany Announcements
Satellos Advances in Duchenne Muscular Dystrophy Trial
PremiumCompany Announcements
Satellos Bioscience Joins Rare Disease Summit
PremiumCompany Announcements
Satellos Bioscience to Host Duchenne Investor WebinarPremiumCompany Announcements
Satellos Bioscience Strengthens Board with New Appointment
PremiumCompany Announcements
Satellos Bioscience Strengthens Board with Key AppointmentPremiumCompany Announcements
Satellos Bioscience Advances in DMD Treatment TrialsOptions Prices
Currently, No data available
---
Ownership Overview
MSCLF FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was $0.27 and its highest was $0.94 in the past 12 months.
What is Satellos Bioscience’s market cap?
Currently, no data Available
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Mar 27, 2025 which is in 94 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Nov 13, 2024. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of -$0.035 by -$0.021.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -$0.03.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 113,430,820 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -$0.056 in its last earnings report, missing expectations of -$0.035. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in MSCLF
---
Satellos Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.77 (26.23% Upside)
$0.77 (26.23% Upside)
Insider Transactions
Bought Shares
Worth $320.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.29%
12-Months-Change
Fundamentals
Return on Equity
-84.66%
Trailing 12-Months
Asset Growth
-50.23%
Trailing 12-Months
Company Description
Satellos Bioscience
iCo Therapeutics, Inc. engages in the business of identification, development and commercialization of drug candidates for the treatment of sight- and life-threatening diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.
---
MSCLF Stock 12 Month Forecast
Average Price Target
$0.77
▲(26.23% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
Plus Therapeutics
―
Cellectar Biosciences
―
Gilead Sciences
―
Johnson & Johnson
―
Best Analysts Covering MSCLF
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+48.33%
reiterated a buy rating last month
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +48.33% per trade.
---